Remove Community Remove Complication Remove Manufacturing Remove Presentation
article thumbnail

The Most Engaging Decision You’ll Read All Year – Five Stars

FDA Law Blog

FDA , Petitioners, a liquid nicotine manufacturer, sued FDA arguing that the Agency was arbitrary and capricious in rejecting the Petitioner’s Premarket Tobacco Application (“PMTA”) in violation of the Administrative Procedure Act (“APA”). FDA also directed manufacturers to produce detailed marketing plans.

article thumbnail

Urinary Incontinence Revisited: George Kuchel & Alison Huang

GeriPal

Incontinence and avoiding issues can present in an older individual, in some cases, just like they do a younger person. But then there is incontinence, which is the same term, same word, but actually presents as a geriatric syndrome. Is this just a bladder problem, or is this a bigger geriatric syndrome problem? Alison 29:08 Yes.

IT 120
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Advance Care Planning Discussion: Susan Hickman, Sean Morrison, Rebecca Sudore, and Bob Arnold

GeriPal

Although, certainly when you start facing complications of serious illness, it is increasingly important to engage as individuals and conversations about goals, values, and preferences. I know not all systems are set up to allow for that or facilitate that retrieval, which makes things a little bit more complicated when push comes to shove.

Illness 72
article thumbnail

Buckle Up: DOJ Initiates Rulemaking to Reschedule Marijuana

FDA Law Blog

The Attorney General, after considering HHS’ recommendations, “concludes that there is, at present, substantial evidence that marijuana does not warrant control under schedule I.” The Attorney General also released DOJ’s Office of Legal Counsel (“OLC”) opinions providing the rationale and support for the NPRM. NPRM at 44,619. NPRM at 44,607.

article thumbnail

Arsenicum album for Kerala school students: a bogus prophylaxis

Tiny Physician

However, there is no clinical trial on its effect on COVID 19 infection or its complications. Later, due to mass outrage from the scientific community, the label of ‘drug for treatment’ was changed to ‘immunity booster’ (5). Without well-designed clinical trials, how can we allow this drug to be given to our children?